Featured Research

from universities, journals, and other organizations

Aprotinin Used In Heart Surgery Associated With Increased Risk Of Death, Study Shows

Date:
May 16, 2008
Source:
Ottawa Health Research Institute
Summary:
Aprotinin is associated with a 50 percent increase in the relative risk of death, according to a major Canadian clinical trial comparing three drugs routinely used to prevent blood loss during heart surgery. The trial shows that approximately six per cent of patients who received aprotinin died within 30 days of surgery compared to four per cent of patients who received tranexamic acid or aminocaproic acid.

Aprotinin is associated with a 50 per cent increase in the relative risk of death, according to a major Canadian clinical trial comparing three drugs routinely used to prevent blood loss during heart surgery. The trial, published in the New England Journal of Medicine, shows that approximately six per cent of patients who received aprotinin died within 30 days of surgery compared to four per cent of patients who received tranexamic acid or aminocaproic acid.

BART (Blood Conservation using Antifibrinolytics in a Randomized Trial) is one of the largest heart surgery trials ever conducted, involving more than 2,000 high-risk cardiac surgery patients and more than 100 cardiac surgeons, anesthesiologists, pharmacists and coordinators from 19 Canadian centres. This publicly-funded collaborative trial was led by Senior Scientists at the Ottawa Health Research Institute, the research arm of The Ottawa Hospital and an affiliated institute of the University of Ottawa.

"These three drugs have been routinely used in heart surgery for more than a decade, but this is the first trial to rigorously compare them in a meaningful setting with meaningful clinical outcomes," said Dr. Dean A. Fergusson, BART Co-Principal Investigator and Senior Scientist. "The results demonstrate the great value of and the need for independent academic clinical trials."

"Overall, our study supports the use of tranexamic acid or aminocaproic acid over aprotinin during high-risk heart surgery," said Dr. Paul C. Hιbert, BART Co-Principal Investigator and Critical Care Physician. "I've treated many patients with complications from heart surgery so I know how important these results are to patients, to their families and to health care providers."

BART was prematurely stopped by the trial's Steering Committee in October 2007 following advice from an independent Data Safety and Monitoring Board, which detected a trend towards increased mortality in one arm of the triple-blinded study. Shortly after these preliminary results were made public, the manufacturer of aprotinin announced that the drug would be suspended from the market pending analysis of the final results of the trial.

The final results show that although aprotinin appeared to decrease some of the consequences of massive bleeding, including the need for repeat surgery, these benefits were outweighed by the risks. The analysis showed that the increased aprotinin-associated mortality was related to cardiac complications.

It has been estimated that between 1 and 1.25 million people undergo heart surgery every year. The use of antifibrinolytics such as aprotinin, tranexamic acid or aminocaproic acid has become standard practice to reduce bleeding during these surgeries. The cost of aprotinin has been estimated at between $1,200 and $1,500 per patient compared to approximately $150 for tranexamic acid or aminocaproic acid.

Stephen Fremes, MD, BART cardiac surgeon, affiliated with the Sunnybrook Health Sciences Centre and the University of Toronto commented: "Prior to the findings of BART, the cardiac surgical community generally considered each of the three drugs to be effective, but that aprotinin was likely more potent. In many institutions, higher risk cardiac surgical patients would receive aprotinin while tranexamic acid or aminocaproic acid were used in lower risk cardiac operations. BART has shown us that tranexamic acid or aminocaproic acid are safer choices for cardiac surgical patients, even in high risk patients."

BART was funded by the Canadian Institutes of Health Research (CIHR) and the Ontario Ministry of Health and Long-Term Care.


Story Source:

The above story is based on materials provided by Ottawa Health Research Institute. Note: Materials may be edited for content and length.


Cite This Page:

Ottawa Health Research Institute. "Aprotinin Used In Heart Surgery Associated With Increased Risk Of Death, Study Shows." ScienceDaily. ScienceDaily, 16 May 2008. <www.sciencedaily.com/releases/2008/05/080514131136.htm>.
Ottawa Health Research Institute. (2008, May 16). Aprotinin Used In Heart Surgery Associated With Increased Risk Of Death, Study Shows. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2008/05/080514131136.htm
Ottawa Health Research Institute. "Aprotinin Used In Heart Surgery Associated With Increased Risk Of Death, Study Shows." ScienceDaily. www.sciencedaily.com/releases/2008/05/080514131136.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) — As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) — Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) — Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) — Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins